Ariana Boswell

Ariana Boswell received her bachelor's degree in biochemistry from Vassar College and is currently pursuing her Master of Public Health in epidemiology at Columbia University Mailman School of Public Health. She has previously conducted research on rare and chronic diseases at Vassar College and Yale School of Medicine and hopes to remain involved in rare disease research and communications in the future. Ariana joined Rare Disease Advisor in 2024.

All articles by Ariana Boswell

Acupuncture may improve sleep & hot flashes in breast cancer

A recent study of breast cancer survivors treated with endocrine therapy found acupuncture may improve sleep quality and reduce hot flashes.
What you should know before starting steroid treatment for breast cancer

Learn more about the risks and benefits of steroid treatment for breast cancer, including tips on how to reduce unwanted side effects.
How do antibody-drug conjugates work in breast cancer treatment?

Learn more about antibody-drug conjugates and how they function as a “smart” chemotherapy to treat breast cancer.
Review: New and emerging therapies for breast cancer

A recent review detailed the mechanisms and applications of numerous classes of drugs designed to treat breast cancer.
Atirmociclib shows early promise in metastatic breast cancer trial

Atirmociclib significantly reduced the risk of disease progression or death in patients with advanced and metastatic breast cancer.
Understanding maintenance therapy in advanced breast cancer

Maintenance therapy can significantly improve overall and progression-free survival in patients with advanced breast cancer.
Fertility preservation options before breast cancer treatment

A breast cancer diagnosis doesn’t mean you can’t have children of your own. There are various options available to help preserve fertility.
First patient dosed in clinical trial for HER2-positive breast cancer

Innovent Biologics has dosed the first patient in their Phase 3 HeriCare-Breast01 trial of IBI354 in HER2-positive breast cancer.
Treatment sequencing in breast cancer: why order matters

The order in which breast cancer treatments are administered can make a major difference in treatment efficacy, quality of life and survival.
FDA approves imlunestrant for advanced and metastatic breast cancer

Imlunestrant has received FDA approval for adults with ER-positive, HER2-negative breast cancer who have mutations in the ESR1 gene.